Amgen's Repatha receives FDA nod; Mylan shareholders vote in favor of Perrigo deal; doctors push for below-average price of experimental cancer drug
Amgen's Repatha will come to market priced $500 lower than the cost of Sanofi and Regeneron's Praluent.
The FDA is expected to announce this week whether it has approved the epilepsy drug as a monotherapy for partial-onset seizures.
The FDA releases biosimilar-naming draft guidance; PD1 drugs linked to a rare type of diabetes; Amgen's PCSK9 inhibitor faces approval decision
The compliance "university" aims to help healthcare agencies and publishers stay up to date on the latest regulatory changes.
Medicaid officials urged to expand access to hepatitis-C drugs; Perrigo is looking to make acquisitions; Sarepta's experimental therapy gets priority review
Longtime ICC leader Viviano moves to the client side to help the start-up build its marketing team and become a commercial contender.
The cloud technology firm announced it will acquire Avalere in a move aimed at growing its relationships with pharma.
Specialty medicines continue to be a hot category, one in which spending has surged behind products that treat medicine's most complex diseases. This eBook lays out the needs and hurdles along the specialty drug pathway, explaining how stakeholders are working to get meds into patients' hands and ease their experience. Click here to download.